Skip to content
Search

Latest Stories

King Charles to undergo treatment for enlarged prostate next week

King Charles to undergo treatment for enlarged prostate next week

Kate Middleton has also been hospitalised for an abdominal surgery

The King’s condition is “benign” and he will be treated in the hospital next week for a “corrective procedure”, Buckingham Palace said a statement released on Wednesday.


“In common with thousands of men each year, the King has sought treatment for an enlarged prostate,” the Palace said.

Because of the upcoming surgery, Charles had to postpone all meetings and events planned for this week.

The Palace informed that the King’s public engagements will be "postponed for a short period of recuperation."

Charles, 75, wanted to share the details of his diagnosis to encourage more men who may be experiencing symptoms to get their conditions checked.

Enlarged prostate is not cancer

As described by National Health Service (NHS), a benign enlarged prostate is common among men over 50. It can affect how people urinate, but it doesn’t usually pose a serious threat to health.

The health service has also clarified have having an enlarged prostate doesn’t make a man vulnerable to developing prostate cancer.

When the King will be able to return to public duties following his surgery is not clear yet.

The same day, in the morning, Kensington Palace had shared news of Kate Middleton's abdominal surgery, but did not give any details about her medical condition.

Kensington Palace said: "The Princess of Wales appreciates the interest this statement will generate.

"She hopes that the public will understand her desire to maintain as much normality for her children as possible; and her wish that her personal medical information remains private."

The 42-year-old was admitted to a private London clinic on Tuesday, and she is expected to remain there for up to two weeks and return to her duties after Easter.

The statement from the palace only mentions that her condition is non-cancerous and that she wished to apologise for postponing her upcoming engagements.

“She looks forward to reinstating as many as possible, as soon as possible,” the Palace said.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less